Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping "CONSCIOUS-2"


Phase 3 Results N/A

Summary of Purpose

The aim of this study is to demonstrate that clazosentan, administered as a continuous intravenous infusion at 5 mg/h until Day 14 post aneurysmal subarachnoid hemorrhage (aSAH), reduces the incidence of cerebral vasospasm -related morbidity and all-cause mortality within 6 weeks post-aSAH treated by surgical clipping. The primary endpoint of the study is the occurrence of cerebral vasospasm-related morbidity,...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 9 March 2012.

1 Nov 2007 13 Nov 2007 1 Jul 2010 1 Jul 2010 1 Mar 2012 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics




Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Pharmacokinetics Study
  • Intervention: Parallel Assignment


  • Study Director: Sebastien Roux, MD Actelion